Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | MEN1 | O00255 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.57 |
| ▸ | USP2 | O75604 | 8/20 | 0.57 |
| ▸ | CASP1 | P29466 | 8/20 | 0.57 |
| ▸ | CASP7 | P55210 | 8/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.57 |
| ▸ | BRCA1 | P38398 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.57 |
| ▸ | HBB | P68871 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636471 | 0.89 | MEN1 (0.56) | ALDH1A1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL189768 | 0.85 | HSD17B10 (0.60) | ALDH1A1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL189471 | 0.83 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL189109 | 0.81 | PIK3CA (0.66) | PIK3CA | |
| SCHEMBL1901235 | 0.80 | HSD17B10 (0.65) | ALDH1A1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL1898969 | 0.75 | HSD17B10 (0.45) | ALDH1A1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL13735484 | 0.75 | ADORA2A (0.43) | ALDH1A1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL189700 | 0.72 | ALDH1A1 (0.57) | ALDH1A1CYP1A2USP2CASP1CASP7 | |
| SCHEMBL189326 | 0.71 | ALDH1A1 (0.65) | ALDH1A1CYP1A2USP2CASP1CASP7 | |
| SCHEMBL4636474 | 0.71 | PIK3CA (0.54) | ALDH1A1MEN1KMT2ACYP1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | claimed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| EP-1940839-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | EXELIXIS INC (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | EXELIXIS, INC (US) | 2013-07-04 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | claimed |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS, INC. (US) | 2011-09-29 | — | — | US | claimed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | claimed |
| EP-1940839-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007044813-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| EP-2142543-A1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2008127678-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | ALDH1A1 1153/4885MEN1 3593/4885KMT2A 2707/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4075/4885MEN1 1310/4885KMT2A 1063/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4089/4885MEN1 1096/4885KMT2A 1033/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | ALDH1A1 1678/4885MEN1 1561/4885KMT2A 1217/4885 |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | BTK, MTOR, BCL6 | ALDH1A1 1452/4885MEN1 710/4885KMT2A 964/4885 |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 1690/4885MEN1 2639/4885KMT2A 4359/4885 |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | MTOR, PIK3CA, PIK3CD | ALDH1A1 2766/4885MEN1 2571/4885KMT2A 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.